The proposal to extend the IP waiver under the TRIPS Agreement for COVID-19 diagnostics and therapeutics would worsen the burden on innovators and have disastrous consequences for the American Southwest and the nation.

The proposal to extend the IP waiver under the TRIPS Agreement for COVID-19 diagnostics and therapeutics would worsen the burden on innovators and have disastrous consequences for the American Southwest and the nation.